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Abstract MicroRNA (miR)-199b-5p has been shown to
regulate Hes-1, a downstream effector of the canonical
Notch and noncanonical SHH pathways, whereby it impairs
medulloblastoma (MB) cancer stem cells (CSCs) through a
decrease in the CD133+/CD15+ cell population. Here, we
have developed stable nucleic acid lipid particles (SNALPs)
that encapsulate miR-199b-5p. The efficacy of the miR-
199b-5p delivery by these SNALPs is demonstrated by
significant impairment of Hes-1 levels and CSC markers
in a range of different tumorigenic cell lines: colon (HT-
29, CaCo-2, and SW480), breast (MDA-MB231T and
MCF-7), prostate (PC-3), glioblastoma (U-87), and MB
(Daoy, ONS-76, and UW-228). After treatment with
SNALP miR-199b-5p, there is also impairment of cell pro-
liferation and no signs of apoptosis, as measured by cas-
pases 3/7 activity and annexin V fluorescence cell sorter
analyses. These data strengthen the importance of such
carriers for miRNA delivery, which show no cytotoxic
effects and provide optimal uptake into cells. Thus, efficient
target downregulation in different tumorigenic cell lines will
be the basis for future preclinical studies.
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Abbreviations
CSCs Cancer stem cells
DODAP 1,2-Dioleyl-3-dimethylammonium propane
MB Medulloblastoma
miRs MicroRNAs
MTS 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium)
OMe- O-methyl-
PBS Phosphate-buffered saline
PEG-Cer16 N-Palmitoyl-sphingosine-1-succinyl [methoxy
(polyethylene glycol)2000]
RISC RNA-induced silencing complex
RNAi RNA interference
siRNAs Small interfering RNAs
SNALPs Stable nucleic acid lipid particles
Introduction
Discovery of small (20–30-nucleotide) noncoding RNAs
that can regulate genome and gene expression can be con-
sidered as one of the most significant advances in cancer
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therapy of the last 20 years. Effects of these small RNAs on
gene expression are generally inhibitory, and corresponding
regulatory mechanisms have important roles in all biological
pathways. These include effects on cell proliferation, apo-
ptosis, migration, and differentiation, and thus also on the
functioning of cancer stem cell (CSC) reprogramming and
lineage commitment (Heinrich and Dimmeler 2012).
Among the main categories of RNA silencing, microRNAs
(miRNAs or miRs) are characterized by a double-stranded
precursor and are endogenous regulators of genes that con-
trol developmental timing (Meister and Tuschl 2004).
Primary miRNA transcripts are generated by RNA polymer-
ase II. In the nucleus, the complex containing the RNase III
enzyme Drosha cuts the transcript to release the pre-miRNA
hairpin, which is then exported to the cytoplasm by exportin
5 (XPO5). Here, DICER, an endoribonuclease, trims the
pre-mRNA from the stem–loop to form a double-stranded
miRNA:miRNA complex. This double strand enters into an
RNA-induced silencing complex (RISC) that includes the
miRNA-loaded Argonaut protein (Ago) and GW182, a gly-
cine–tryptophan repeat-containing protein. Only one of the
two strands is stably associated with the Ago effector pro-
tein (Fabian and Sonenberg 2012).
MaturemiRNA duplexes are short lived, as they are rapidly
unwound when they associate with an Ago protein. MiRNA
unwinding is accompanied by differential strand retention;
one strand is retained while the other strand is lost. The
miRNA acts as an adaptor for miRISC to specifically recog-
nize and regulate particular mRNAs. With few exceptions,
miRNA-binding sites in animal mRNAs lie in the 3′-UTR,
and they are usually present in multiple copies. The degree of
miRNA–mRNA complementarity is considered to be the key
determinant of the regulatory mechanism. This allows Ago-
catalyzed cleavage of the mRNA strand, whereas central mis-
matches exclude cleavage and promote repression of mRNA
translation. It is believed that perfect complementarity
excludes translational repression, as it enables cleavage.
Deregulation of miRNA expression has been shown in
many tumors and in their corresponding cell lines, as com-
pared to the normal tissues and cells (Calin and Croce 2006;
Gaur et al. 2007). The first evidence of the involvement of
miRNAs in human cancer is derived from studies on chronic
lymphocytic leukemia (CLL). Chromosome 13q14 is deleted
in over 65 % of CLL patients, and it contains two miRNA
genes,miR-15a and miR-16-1. There is, thus, the loss of these
miRNA activities in patients who have deletion of this region
(Calin et al. 2002). Several review articles on the roles of
miRNAs in human cancers have been published (Calin et al.
2005; Esquela-Kerscher and Slack 2006; Garzon et al. 2009).
Understanding how the expression levels of miRNAs are
finely tuned within a tumorigenic cell and how their gene
target regulation occurs in such a complex of multifunctional
proteins is now under widespread investigation in cancers
(Kim and Nam 2006; Nana-Sinkam and Croce 2011).
Different mechanisms of action have been proposed for the
control of their full processing, including genetic, epigenetic,
and transcriptional regulation mechanisms (Gaur et al. 2007;
He et al. 2007). MiRNAs can function both as oncogenes,
which are known as “oncomirs,” and as tumor suppressors.
Oncomirs are significantly upregulated in different can-
cers and can promote tumor development by inhibition of
tumor suppressors or of genes that control differentiation or
apoptosis (Zhang et al. 2007). Instead, miRNA suppressors
can impair tumor growth, invasion and metastasis forma-
tion, and CSC dynamism. The miRNAs involved in CSC
maintenance have multiple functions, as their gene targets
are involved in different cellular pathways, e.g., Wnt, Notch,
and SHH (Brennecke et al. 2005; de Antonellis et al. 2011;
Zhao et al. 2011; Andolfo et al. 2012; Schoof et al. 2012).
We previously identified miRNA 199b-5p (miR-199b-
5p), which acts as a tumorigenesis suppressor in medullo-
blastoma (MB; a childhood brain tumor), by targeting Hes-
1, and we demonstrated miR-199b-5p deregulation in MB.
Recently, other targets of miR-199b-5p have been identi-
fied: PODXL, DDR1, and HIF-1α (see Garzia et al. 2009;
Wang et al. 2011). In acute myeloid leukemia, decreased
miR-199b-5p leads to upregulation of PODXL-1 and
DDR1, which enhances the proliferation rate of leukemic
stem cells and accelerates cell migration and invasion
(Favreau et al. 2012).
In MB, we demonstrated that miR-199b-5p can impair
the CSC compartment by reducing CD133-positive and
CD15-positive cells via Hes-1 downregulation (Garzia et
al. 2009). Of note, Hes-1 is a target of the canonical Notch
pathway and the noncanonical SHH and Wnt pathways
(Morton and Lewis 2007; Ingram et al. 2008; Shimizu et
al. 2008). A crucial role for the Notch target gene Hes-1 was
emphasized by Schreck et al., who demonstrated Hes-1
binding to the Gli1 first intron and defined its mechanism
of regulation (Schreck et al. 2010). Moreover, in a recent
phase I trial, Fouladi et al. estimated the maximum tolerated
dose of MK-0752 and characterized its pharmacokinetic
properties as a γ-secretase (Notch/Hes-1 pathway) inhibitor
in children with refractory or recurrent central nervous sys-
tem malignancies, such as glioma, ependymoma, and MB
(Fouladi et al. 2011). Indeed, Hes-1 is also regulated by the
SHH pathway, through a mechanism that does not involve
γ-secretase-mediated Notch cleavage and that probably
involves transcription factors other than RBP-Jk in MB
(Morton and Lewis 2007).
It is well known that the Notch pathway has a crucial role
in embryogenesis, tissue patterning, and morphogenesis and
its dysfunction can occur in a wide range of tumors, from
hematological cancers, such as leukemia and lymphoma, to
solid tumors, such as colon, prostate, and brain tumors
(Fouladi et al. 2011; Bertrand et al. 2012; Danza et al.
Naunyn-Schmiedeberg's Arch Pharmacol
2012; Gursel et al. 2012). Many studies have highlighted the
activation of the Notch pathway in colon cancer, and in
particular, Hes-1 expression was shown to be higher in
primary tumors than in distant metastases (Katoh and
Katoh 2007; Reedijk et al. 2008). In breast cancer, instead,
Mittal et al. showed high expression of Hes-1 in almost
75 % of breast cancers analyzed (Mittal et al. 2009).
Gene silencing by RNA interference (RNAi) has become
the optimal method for target gene identification and valida-
tion (Dorsett and Tuschl 2004). In mammalian cells, it has
been reported that siRNA actions remain effective only for an
average of ca. 66 h (Chiu and Rana 2002) because of poor
nuclease resistance and the unfavorable metabolic and thermal
stability arising from their short oligoribonucleotide sequen-
ces (Bumcrot et al. 2006). In addition, it has been shown that
siRNAs induce an innate immune stimulation in vivo, with
high levels of inflammatory cytokines, such as tumor necrosis
factor-α, interleukin-6, and interferon-α, with effects on the
regulation of gene expression (Robbins et al. 2009). To im-
prove the nuclease resistance and thermal stability of siRNAs,
several chemical modifications to their sugar and phosphate
backbone have been attempted (Watts et al. 2008). In partic-
ular, 2′-O-methyl (2′-OMe) modifications have provided
increases in stability that correlate to the number of substitu-
tions (Czauderna et al. 2003), thus preventing the innate
immune responses indicated above (Judge et al. 2006).
Despite such modifications that can increase the effective-
ness of RNAi, the therapeutic potential of miRNAs is ham-
pered by other drawbacks, such as poor cell uptake and
degradation in the lysosomal compartments (Whitehead et al.
2009). The use of viral carriers allows high transfection effi-
ciency to be achieved, although this approach is very expen-
sive and can be dangerous due to immunogenicity and possible
viral reactivation. Conversely, nonviral carriers are relatively
cheap, safe, and easy to manipulate, as compared to viral
carriers. Many different types of nonviral carriers have been
developed to provide solutions to successful tumor targeting of
siRNAs. Lipid-based nanoparticles are now, by far, the most
widely used and studied nanocarriers for cancer therapy
(Moreira et al. 2008). Among various lipid-based formulations,
a classical example is the use of “liposomes”, while an
emerging novel class are the so-called solid lipid nanoparticles
or nanostructure lipid carriers (Puri et al. 2009). Of note, recent
preclinical studies using biocompatible polymers, such as
poly-lactic-co-glycolic acid carrying miRNA-155, together
with the use of a “penetratin” peptide, have shown therapeutic
benefit in a lymphoma animal model (Babar et al. 2011). Most
recently, nanoparticle-sized issues are under investigation be-
cause of their efficacy for internalization in eukaryotic cells.
Martins et al. showed that different tumorigenic cell lines
(glioma and macrophage) can internalize lipid nanoparticles
with mean diameter <200 nm and with a slightly negative
surface charge (−20 mV) (Martins et al. 2012).
For the delivery of nucleic acids, including siRNAs, cat-
ionic liposomes have been the most extensively used (Moreira
et al. 2008). Complexing of cationic liposomes with negative-
ly charged siRNAs generates lipoplexes with high efficacy for
mediation of siRNA transfection (Simoes et al. 2005). For use
in vivo, where it is necessary to provide protection from blood
nucleases and to extend their blood circulation, these cationic
liposomes have been protected with hydrophilic molecules,
such as poly(ethyleneglycol) (PEG) (Gomes-da-Silva et al.
2012). The most notable of the PEG formulations are the
“stable nucleic acid lipid particles” or SNALPs (Morrissey
et al. 2005; Judge et al. 2009). SNALPs have been success-
fully used to aid in the silencing of therapeutically relevant
genes in rodents and in nonhuman primates (Zimmermann et
al. 2006; Frank-Kamenetsky et al. 2008). Morrissey et al.
described the efficacies of SNALPs (with a size of 140±
12 nm) that encapsulate siRNAs targeted to HBV RNA in a
mouse model of HBV replication. Here, they showed a longer
half-life in plasma and liver and reduced toxic and immunos-
timulatory side effects (Morrissey et al. 2005). Yang et al.
instead described cationic lipid-assisted polymeric nanopar-
ticles of (poly(ethylene glycol)-b-poly(d,l-lactide) at around
170 to 200 nm in size, which were used to suppress tumor
growth in an MDA-MB-435 murine xenograft model and
which suggested therapeutic promise in disease treatment
(Yang et al. 2011). Additional improvements have shown
significant efficacy in vivo, with the development of new
cationic lipids in formulations to deliver siRNAs in rodents
and nonhuman primates (Semple et al. 2010). These have used
1,2-dilinoleyloxy-3-dimethylaminopropane substituted with
new molecules, such as 2,2-dilinoleyl-4-(2-dimethyl amino-
ethyl)-[1,3]-dioxolane.
Due to the previous data obtained in MB with miR-199b-
5p and to the deregulation of the Notch pathway in several
tumor types, we investigated the development of a SNALP
formulation to deliver miR-199b-5p into different cancer
cell lines in vitro. Thus, we prepared and characterized
SNALPs that can encapsulate the mature 2′-O-methylated
(2′-OMe)-miR-199b-5p. This formulation was investigated
in a range of different human cancer cell lines (colon, breast,
prostate, and brain) to define the SNALP encapsulation of
miR-199b-5p and their combined actions, which are mainly
through Hes-1 inhibition.
Materials and methods
Lipids and chemicals
1,2-Dioleyl-3-dimethylammonium propane (DODAP) and
N-palmitoyl-sphingosine-1-succinyl [methoxy(polyethylene
glycol)2000] (PEG-Cer16) were purchased from Avanti
Polar Lipids. Disteroylphosphatidylcholine (DSPC) was
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kindly donated by Lipoid GmbH (Cam, Switzerland).
Cholesterol, sodium chloride, potassium chloride, sodium
phosphate, HEPES, citric acid, and sodium citrate were
purchased from Sigma-Aldrich (Milan, Italy). Ethanol and
other reagents were obtained from Carlo Erba Reagenti
(Milan, Italy).
2′-OMe–oligonucleotide synthesis and purification
The 2′-OMe–oligonucleotides were synthesized on a
Millipore Cyclone Plus DNA synthesizer at a 1 μmol
scale using commercially available 5′-O-(4,4′-dimethoxy-
trityl)-2′-OMe-3′-O-(2-cyanoethyl-N,N-diisopropyl) RNA
phosphoramidite monomers and 2′-OMe RNA SynBase
CPG 1000/110 as the solid-phase support (Link
Technologies). The sequence of the mature miR-199b-5p
(2′-OMe is inserted into each following nucleotide) is: 5′-
C C C A G U G U U U A G A C U A U C U G U U C - 3 ′
(MIMAT0000263, miRBase 18 released; www.mirbase.org)
and its scrambled control (2′-OMe in each base) was: 5′-
GGUUGUAUGCAUUCCCUAUCUAC-3′. The oligomers
were detached from the support and deprotected by treatment
with concentrated aqueous ammonia for 12 h at 55 °C. The
combined filtrates and washings were concentrated under
reduced pressure, dissolved in H2O, and analyzed and purified
by anion exchange high-performance liquid chromatography
on a NUCLEOGEL SAX column (Macherey-Nagel, 1000-8/
46) using buffer A: 20 mM KH2PO4/K2HPO4 aqueous solu-
tion (pH 7.0), containing 20 % (v/v) CH3CN; and buffer B:
1 M KCl, 20 mM KH2PO4/K2HPO4 aqueous solution (pH
7.0), containing 20 % (v/v) CH3CN. These were used as a
linear gradient from 0 % B to 100 % B over 45 min at a flow
rate of 1 ml/min. The purified oligomers were successively
desalted using Sep-Pak C18 cartridges (Waters) and charac-
terized by electroionization mass spectrometry.
Preparation and characterization of stable nucleic acid lipid
particles
Lipid stock solutions were prepared in ethanol. Typically,
6.5 μmol total lipid (0.2 ml total volume) was added to a glass
tube. In a separated tube, 1 mg miRNA was dissolved in
0.3 ml 20 mM citric acid, pH 4.0. The two solutions were
warmed for 2–3 min at 65 °C, and the lipid solution was
quickly added to the miRNA solution while stirring. The
mixture was passed 30 times through three-stacked 100-nm
polycarbonate filters using a thermobarrel extruder (Northern
Lipids Inc., Vancouver, BC, Canada) maintained at approxi-
mately 65 °C. Nonencapsulated miRNA was removed by
chromatography using a Sephadex G-50 DNA grade column
(GE Healthcare, Milan, Italy). A typical 0.5 ml formulation
contained 6.5 μmol DSPC/cholesterol/DODAP/PEG-Cer16
(25 mol/45 mol/20 mol/10 mol) and 1 mg miRNA. The
encapsulation efficiency was about 80 %. The mean diameter
and size distribution of the SNALPs were determined at 37 °C
by Nano-Zs (Malvern, UK). Each sample was diluted in
phosphate-buffered saline (PBS), filtered with 0.22-μm pore
size polycarbonate filters (MF-Millipore, Microglass Heim,
Naples, Italy), and analyzed with the detector angle at 173°.
The polydispersity index was measured to determine the
particle size distribution. For each batch, the diameter and size
distributions were calculated as the means of three measures.
For each formulation, the diameter and polydispersity index
were calculated as the means of two different batches.
The 1 μmol of miRNA encapsulated in the SNALPs were
measured spectrophotometrically. Briefly, 2 μl SNALP sus-
pension was analyzed at 260 nm using a nanoprobe (Thema
Research, Bologna, Italy), and the encapsulation efficiencies
were calculated as the ratio of the initial and final
oligodeoxynucleotide-to-lipid ratios (×100).
Cell culture
Different cell lines were used in this study: three derived
from colon cancers (HT-29 cells, code ATCC #HTB-38,
Manassas, VA, USA; CaCo-2 and SW480 cells from the
Culture Tissues Facility, CEINGE, Naples, Italy), two from
breast cancers (MDA-MB231T cells, ATCC code HTB-26,
Manassas, VA, USA; MCF-7 cells, from the Culture Tissues
Facility, CEINGE, Naples, Italy), one from prostate cancer
(PC-3 cells, code PC-3 M, Caliper, Paris, France), one from
glioblastoma (U-87 cells, code U-87 MG, Caliper, Paris,
France), and three from MB (Daoy, UW-228 and ONS-76,
ATCC #HTB-186, #14963, and # HTB-182, respectively,
Manassas, VA, USA). The HT-29 and MDA-MB231T cells
were cultured in Dulbecco's modified Eagle's medium
(DMEM) (EuroClone, Pero, Italy); the Daoy, UW-228, U-
87, PC-3, and MCF-7 cells were cultured in minimum
essential Eagle's medium (M5650; Sigma-Aldrich, Milan,
Italy); and the SW480 and ONS-76 cells were cultured in
RPMI 1640 (EuroClone, Pero, Italy). All of the media were
supplemented with 10 % fetal bovine serum, 2.0 mM L-
glutamine, 1.0 mM sodium pyruvate, 100 μg/ml streptomy-
cin, and 100 U/ml penicillin G, with the cells kept at 37 °C
in a 5 % CO2 and 95 % air humidified atmosphere. The cell
lines were grown in 10-cm plates.
Transient transfection and luciferase assay
Human embryonic kidney (HEK-293T) cells were cultured
in DMEM containing 10 % fetal bovine serum, 2.0 mM L-
glutamine, and 1 % penicillin/streptomycin in a humidified
atmosphere with 5 % CO2. For transfection, the HEK-293T
cells were plated and incubated overnight at 37 °C. The
following day, immediately prior to transfection, their me-
dium was changed. The transfections were carried out using
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calcium phosphate according to the standard protocol.
When at 60 % confluence, the HEK-293T cells were trans-
fected with 15 μg DNA per 10-cm dish using vectors
encoding the Hes-1 3′-UTR (TK-Renilla Hes-1). After
12 h, the SNALP miR-199b-5p and SNALP with the scram-
bled miRNA (SNALP scramble) were added. The following
day, the medium was changed, and reporter assays were
performed after 48 h and 72 h using the Dual-Luciferase®
Assay reporter system (Promega, Madison, WI, USA)
according to the manufacturer instructions.
Treatment of cell lines with the SNALPs
The HT-29, CaCo-2, SW480, MCF-7, PC-3, U-87, ONS-76,
Daoy, UW-228, and MDA-MB231T cells were seeded in
duplicate into six-well plates at a density of 2.5×105 cells/-
well. After their attachment, they were treated with medium
without serum but containing the SNALPs (25 μg/ml or
50 μg/ml miR-199b-5p oligonucleotide, as the standard
miRNA concentrations throughout the study) for 8 h at
37 °C in a 5 % CO2 incubator. After this time, the medium
was replaced with medium containing fetal bovine serum for
the following 72 h and then the cells were pelleted for
further analyses.
Proliferation assay
Cell proliferation was determined using CellTiter96
AQueous Nonradioactive Cell Proliferation Assay kits
(Promega Madison, WI, USA). The HT-29, MDA-
MB231T, Daoy, and UW-228 cells were seeded into 96-
well plates at a density of 3×103 cells/well in complete
DMEM or minimum essential Eagle's medium, with
SNALP miR-199b-5p and SNALP scramble at a final con-
centration of 50 μg/ml. After 24, 48, and 72 h, 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) (MTS) was added to each
well, and after 2 h, the absorbance of each well was mea-
sured at 490 nm using a VICTOR3 Multilabel counter
(PerkinElmer, Monza, Italy). Each experiment was per-
formed with five replicates (wells) and was repeated twice.
Cell index proliferation assay
The cell index (CI) was derived as the relative change in the
measured electrical impedance, as representative of the cell
status. This assay allows label-free dynamic monitoring of
cell proliferation and viability in real-time. The CaCo-2,
SW480, MCF-7, PC-3, U-87, and ONS-76 cells were seed-
ed at 5,000 cells/well into 100 μl complete medium in 96-
well microtiter plates (E-plates). The attachment, spreading,
and proliferation of the cells were monitored every 30 min
using the RT-CES® system (xCELLigence by Roche).
Approximately 24 h after seeding and after 3 h of starvation,
the cells were treated with 100 μl SNALP miR-199b-5p and
SNALP scramble (50 μg/ml) in medium without serum for
4 h. After this time, 100 μl medium was added to each well,
and the cell proliferation was monitored for 24 h to 130 h,
depending on experimental design. The CI at each time
point was defined as (Rn − Rb) / 15, where Rn is the cell
electrode impedance of the well when it contained cells, and
Rb is the background impedance of the well with medium
alone.
RNA isolation, cDNA preparation, and quantitative
real-time PCR
Total RNA was extracted from the cell lines using TRIzol
reagent (Invitrogen). Synthesis of cDNA from the total
RNA (2 μg) was with SuperScript II First-Strand kits
(Invitrogen). Quantitative real-time PCR (qRT-PCR) was
performed using the SYBR Green method, following stan-
dard protocols, with an Applied Biosystems ABI PRISM
7900HT Sequence Detection system. Relative gene expres-
sion was calculated using the 2(−ΔCt) method, where ΔCt
indicates the differences in the mean Ct between selected
genes and the internal control (Livak and Schmittgen 2001).
qRT-PCR primers for each gene were designed using the
Primer Express software, version 2.0 (Applied Biosystems).
The primer sequences are indicated below: HES-1 forward,
(5′–3′) AATGACAGTGAAGCACCTCCG; HES-1 reverse,
(3′–5′) CACTTGGGTCTGTGCTCAGC; PODXL-1 for-
ward, (5′–3′) TCAAGCACTGTGGCTATCCCT; PODXL-1
reverse, (3′–5′) TCAAGCACTGGCTATCCCT; DDR1 for-
ward, (5′–3′) CTGGATGGGCTGGAAGGA; DDR1 re-
verse, (3′–5′) TCCTTCAGCACCACTCCCTC; HIF-α
forward, (5′–3′) CTCAGTCGACACAGCCTGGA; HIF-α
reverse, (3′–5′) TTCTTCTGGCTCATATCCCATCA. The
significance of the gene expression differences were deter-
mined using the Student's t test; statistical significance was
established as p<0.05. All statistical analysis was performed
using Excel, included in the Office 2007 suite released by
Microsoft.
TaqMan miRNA assay
Reverse transcriptase reactions
The reverse transcriptase reactions for miR-199b-5p and
mMU6 were performed with 40 ng RNA, 50 nM stem–loop
reverse transcriptase primer, 1× reverse transcriptase buffer
(P/N: 4319981, Applied Biosystems, Branchberg, NJ, USA),
0.25 mM of each dNTP, 3.33 U/ml MultiScribe Reverse
Transcriptase (P/N: 4319983, Applied Biosystems), and 0.25
U/ml RNase inhibitor (P/N: N8080119; Applied Biosystems).
The 15-μl reactions were incubated in an Applied Biosystems
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9700 thermocycler for 30 min at 16 °C, 30 min at 42 °C, and
5 min at 85 °C and then held at 4 °C.
Real-time PCR
RT-PCR was performed for all of the cell lines analyzed using
a standard TaqMan PCR kit protocol on an Applied
Biosystems 7900HT Sequence Detection system. The 20-μl
PCRs included 2 μl reverse transcriptase product, 10 μl
TaqMan Universal PCR Master Mix (Applied Biosystems),
and 0.2 mM TaqMan probe (Applied Biosystems: MiR-miR-
199b-5p: identification number 00500, code 4427975; MU6:
identification number 001093, code 4427975). The reactions
were incubated in 96-well plates at 95 °C for 10 min, followed
by 60 cycles of 95 °C for 15 s, and 60 °C for 1 min.
Western blotting
Western blotting was performed on the total protein extracts of
the human cancer cell lines for the HT-29, CaCo-2, SW480,
MDA-MB231T, MCF-7, PC-3, U-87, ONS-76, Daoy, and
UW-228 cells after 72 h of treatment. For the total protein
fraction, the harvested cells were washed three times with ice-
cold PBS and lysed in RIPA buffer. Protein concentrations in
cell extracts were determined using the Bradford assay
(BioRad, Milan, Italy). Fifty microgram total lysates was
loaded onto 12 % polyacrilamide gels and then transferred
to nitrocellulose membranes. The membranes were blocked
with 5 % nonfat milk in PBS, pH 7.6, 0.02% Tween 20 for 1 h
and then incubated with the relevant polyclonal antibody:
anti-Hes-1 (1:200; sc 25392; Santa Cruz Biotechnology),
anti-CD15 (1:250; sc 53290; Santa Cruz Biotechnology),
anti-CD133 (1:250; ab 16518; Abcam), and anti-CD44
(1 μg/ml; ab 41478; Abcam). After washing in PBS, pH 7.6,
0.02 % Tween 20, the membranes were incubated with a
horseradish peroxidase-conjugated goat anti-rabbit antibody
(1:3,000) and a horseradish peroxidase-conjugated goat anti-
mouse antibody (1:5,000; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The immunoblots were visualized using
ECL detection kits, with enhanced chemiluminescence
(Pierce, Rockford, IL, USA). A mouse β-actin antibody
(1:1,000; Sigma-Aldrich, Milan, Italy) was used as the control
for equal loading of total lysates.
Results
Characteristics of SNALP miR-199b-5p
The methodology for SNALP production used here was
through “membrane extrusion,” in contrast to the “high-pres-
sure homogenization” methodology that is usually used in
industrial production to obtain reliable and homogeneous
populations of nanoparticles (with a size range <100 nm).
For this reason, the SNALPs developed here were in a range
of sizes >100 nm; nevertheless, Martins et al. showed that
such particles can internalize in cells in vitro, as for those used
in solid lipid nanoparticle formulations (Jores et al. 2005;
Martins et al. 2012). The SNALPs containing miR-199b-5p
were characterized by measuring their size, surface properties,
and miR-199b-5p oligonucleotide loading. Here, we encapsu-
lated the mature single-strand miR-199b-5p in the SNALP
molecules to study its biological effects in different cell lines.
As is known, RNAi, as a single-strand status, is less resistant
than siRNA duplexes. We used the 2′-OMe modification for
each of the following nucleotides to impair nuclease degrada-
tion and to improve miR-199b-5p thermal stability. The char-
acteristics of the SNALP miR-199b-5p are reported in
Table 1. The SNALPs with the scrambled miRNA (SNALP
scramble) included two populations, one at ca. 199.6 nm in
size and the second at ca. 78.4 nm; the SNALP miR-199b-5p,
instead, showed two main population peaks: the first at ca.
258.8 nm and the second at ca. 84.7 nm (see Table 1). Our
SNALP production had a polydispersivity index (PI) of ca.
0.2. The negative zeta potential showed the absence of a net
positive charge on the SNALP surface. Finally, the miR-199b-
5p encapsulation efficiency was measured as close to 80 %.
SNALP miR-199b-5p binds to the 3′-UTR of Hes-1
In our previous study, we demonstrated that miR-199b-5p
binds to the 3′-UTR of its predicted target gene Hes-1 and
significantly impairs Hes-1 expression (Garzia et al. 2009).
Thus, one of the major initial questions raised here was
whether miR-199b-5p encapsulated in the SNALPs has these
same effects in terms of its target recognition. For this pur-
pose, we used a Renilla luciferase reporter that contained the
3′-UTR of the human Hes-1 mRNA downstream of the
Renilla luciferase coding region, the expression of which
was driven by the thymidine kinase (Tk) promoter
(Supplementary Fig. 1a). The reporter construct (Tk-
ren/Hes-1) and the SNALP miR-199b-5p were transfected
into HEK-293T cells over 48 h and 72 h, with the pGL3-
CMV-firefly vector to normalize for transfection efficiency.
Two different concentrations of SNALP miR-199b-5p and
SNALP scramble were used: 25 μg/ml and 50 μg/ml. The
experiments carried out with 25 μg/ml SNALP miR-199b-5p
had no significant effects on luciferase activity (data not
shown). Interestingly, the relative luciferase activity was
markedly decreased in cells transfected with the Tk-ren/Hes-
1 construct and treatedwith SNALPmiR-199b-5p (50μg/ml),
compared to SNALP scramble. The values of luciferin activity
observed were significantly higher at 72 h (by ca. 60 %) than
at 48 h (p=0.02; Supplementary Fig. 1a). No variations were
measured for the relative luciferase activity assays within the
treated HEK-293 T cells with either empty SNALPs or
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SNALP scramble (Supplementary Fig. 1a). One explanation
for this negative downregulation of Hes-1 using 25 μg/ml
SNALP miR-199b-5p would be due to the presence of the
two different size populations of the SNALP nanoparticles (as
shown in Table 1). Here, we measured two peaks of particle
elution, with size ranges between 70–84 nm (as 44 % of the
SNALP population) and 250–258 nm (as 57 % of the SNALP
population). The data obtained with the scrambled miRNA-
containing SNALPs (SNALP scramble) showed similar size
values of the second peak, which ranged from 72 to 78 nm,
with a substantial difference in the volume (reduced to 14 %,
on average). Overall, our data are in agreement with literature
reports that have shown that this second peak population
(<100 nm in size) can enter eukaryotic cells more efficiently
than other population sizes. Thus, at this time, we can assume
that the SNALPs with the smaller diameters (<100 nm) can
carry the miR-199b-5p into tumorigenic cells with good in-
ternalization and with binding to the 3′-UTR ofHes-1mRNA,
which showed reduced expression and protein synthesis.
Delivery of miR-199b-5p by SNALPs compared to “naked”
oligonucleotide
To investigate the efficiency of miR-199b-5p delivery by the
SNALPs as compared to the “naked” miR-199b-5p oligo-
nucleotide (not encapsulated in SNALPs), we treated HT-29
colon cancer cells for 72 h, according to previously obtained
luciferase assay data. At this time, we performed TaqMan
RT-PCR assays to compare the expression of miR-199b-5p
in the HT-29 cells after these two different treatments. As
shown in Supplementary Fig. 1c, the expression of miR-
199b-5p did not change in cells treated with the “naked”
oligonucleotide, as compared to the untreated cells (which
showed the endogenous levels of miR-199b-5p in these HT-
29 cells), while the expression of miR-199b-5p was in-
creased after treatment with SNALP miR-199b-5p
(Supplementary Fig. 1c). Hes-1 expression was further test-
ed in cells treated with the “naked” miR-199b-5p,
confirming that it cannot enter the cells to downregulate
Hes-1 expression (Supplementary Fig. 1c).
Impaired proliferation rates by SNALP miR-199b-5p
in different tumorigenic cell lines
We have previously demonstrated that miR-199b-5p impairs
cell proliferation in MB cell stable clones overexpressing
miR-199b-5p, thus showing that this phenomenon is direct-
ly correlated with Hes-1 downregulation (Garzia et al.
2009). Here, to determine whether SNALP miR-199b-5p
delivery has similar biologic effects in different cell lines,
we performed proliferation assays. We initially treated HT-
29 cells with 25 μg/ml SNALP miR-199b-5p and SNALP
scramble for up to 72 h. The efficiency of the delivery of the
SNALPs was monitored through analysis of miR-199b-5p
expression using the TaqMan RT-PCR assay. As shown in
Supplementary Fig. 1b, at 72 h, there was significant over-
expression of miR-199b-5p in cells treated with SNALP
miR-199b-5p (to ca. fivefold the control). The cell prolifer-
ation rate, which was determined using MTS (see “Materials
and methods”), and the Hes-1 protein expression were not
impaired at this concentration of SNALP miR-199b-5p
(Supplementary Fig. 1b). These data are similar to those
obtained in the HT-29 cell line with the luciferase assay,
where 25 μg/ml SNALP miR-199b-5p had no effects on
Hes-1 downregulation and impairment of the cell prolifera-
tion rate.
To set up the optimal conditions for our SNALP miR-
199b-5p treatments, we tested a time course of sampling at
3, 6, 9, 12, 24, and 72 h using 50 μg/ml SNALP miR-199b-
5p and SNALP scramble, following the effects on Hes-1
express ion in HT-29 cel ls by Western blot t ing
(Supplementary Fig. 1d, e). Indeed, here, we observed that
miR-199b-5p expression gradually increased (at 6 and
12 h), although at the early time points (3, 6, 9, 12, and
24 h), there were no significant changes in the cell prolifer-
ation rate and Hes-1 protein expression. For these reasons,
Table 1 Structural characteristics of the SNALP miR-199b-5p and scramble liposome formulations
Formulation Mean diameter peak
1 (nm ± SD)
% volume peak 1 Mean diameter peak
2 (nm ± SD)
% volume peak 2 Polydispersity
index ± SD
Zeta potential
(mV ± SD)
SNALP miR-199b-5p
Batch 1 250.0±6.84 57.7 70.64±4.42 42.3 0.267±0.001 −5.09±0.11
Batch 2 258.8±7.72 55.3 84.66±2.92 44.7 0.257±0.001 −7.03±0.19
SNALP scramble
Batch 1 194.0±5.08 84.5 72.38±3.02 15.5 0.175±0.006 −10.71±0.34
Batch 2 199.6±4.47 87.4 78.46±2.46 12.5 0.135±0.008 −14.49±0.31
Zeta potential, size, and percentage in volume of liposome formulation are expressed as z-average, as measured by DSL and polydispersivity index.
Data are expressed as means±standard deviation (SD) of three separate experiments for each of two batch formulations, with at least 13
measurements for each
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we used the HT-29 cells for SNALP miR-199b-5p treat-
ments of 72 h, with 50 μg/ml SNALP miR-199b-5p and
SNALP scramble. At this treatment time, we measured the
expression of miR-199b-5p using TaqMan RT-PCR assays.
As shown in Supplementary Fig. 2a, the levels of miR-
199b-5p were significantly higher in cells treated with
50 μg/ml SNALP miR-199b-5p (p=0.008), as compared
to those treated with 50 μg/ml SNALP scramble. Also, the
proliferation rate of these HT-29 cells, as determined using
the MTS assay (see “Materials and methods”), was signifi-
cantly impaired at the same SNALP miR-199b-5p concen-
tration (p=0.03), as shown in Supplementary Fig. 2a (data
presented for the HT-29, Daoy, UW-228, and MDA-MB-
231T cells). According to the luciferase assays, our data
demonstrate that miR-199b-5p delivery by SNALPs (at
50 μg/ml) was efficient in these HT-29 cells at 72 h post-
treatment and that after this time, there was significant
impairment of cell proliferation due to the overexpression
of miR-199b-5p.
Efficiency of SNALP miR-199b-5p delivery and impairment
of proliferation in different cell lines
To further address the ubiquitous delivery of these SNALPs
in several tumorigenic cell lines, we investigated other cel-
lular models for the efficiency of SNALP delivery of miR-
199b-5p. For this, we treated several cell lines from different
tumor types with 50 μg/ml SNALP miR-199b-5p, and
through TaqMan RT-PCR assays, this revealed the expres-
sion of miR-199b-5p after 72 h of treatment. CaCo, SW480,
MCF-7, PC-3, U-87, ONS-76, Daoy, UW-228, and MDA-
MB231T cells were used here. As shown in Fig. 1, by
measuring the mRNA levels of exogenous miR199-b-5p in
all of these cell lines analyzed, we saw that internalization of
miR-199b-5p was already achieved at 24 h of treatment,
although at 72 h the fold changes observed were significant-
ly greater. Moreover, after the same treatment with SNALP
miR-199b-5p (50 μg/ml) for 72 h, we observed a different
efficacy of miR-199b-5p internalization, potentially due to
the different lipid compositions of the cell membranes of
these different cell types and to their levels of endocytosis.
These are artifacts that can infer differences in the intracel-
lular acquisition of these particles according to the specific
cell membrane structure and composition. At 72 h, we
measured the optimum internalization of these SNALPs in
the ONS-76 cells (p=0.003) (Fig. 1f), followed by the
CaCo-2 (p=0.004) (Fig. 1a), SW480 (p=0.0007) (Fig. 1b),
MCF-7 (p=<0.0001) (Fig. 1c), U-87 (p=0.0008) (Fig. 1e),
PC-3 (p=0.012) (Fig. 1d), and MDA-MB231T (p=0.0002)
(Supplementary Fig. 2a) cells. Lower levels of internalization
were measured in the Daoy (p=0.150) and UW-228 (p=0.001)
cells, as shown in Supplementary Fig. 2a. The histogram in
Supplementary Fig. 2b shows the levels of miR-199b-5p ex-
pression after this treatment in all of the cell lines (for 2ΔCt
values see Supplementary Table 2).
To confirm the previous data on the impairment of cell
proliferation, as obtained in HT-29 cells, we performed CI
analyses or MTS assays in all of these cell lines, with the
analysis by TaqMan RT-PCR. Thus, to monitor the effects of
SNALP miR-199b-5p on cell proliferation in real-time, we
used the CI assay with the CaCo-2, SW480, MCF-7, PC-3,
U-87, and ONS-76 cells (for impedance values, see
Supplementary Table 1). As shown in Fig. 1, 50 μg/ml
SNALP miR-199b-5p significantly impaired the prolifera-
tion of all of these treated cells, with greater effects around
72 h (CI p values <0.0001 for all tumorigenic cells treated),
in agreement with the TaqMan RT-PCR for miR-199b-5p
expression in the same cell lines. After 72 h, we observed no
significant variations, and we speculate that this is due to the
time of the intracellular stability of 2′-OMe-miR-199b-5p.
Indeed, as shown by Takahashi et al. (2012), although the
2′-OMe modification appears to be valid for the duration of
oligonucleotide stability in cells and for its interference
activity, after 72 h, 2′-O-Me siRNAs show drastic reductions
in their activities. Finally, to confirm the impairment of
proliferation also in other cell lines, we used an additional
method to measure cell proliferation, the classical MTS
assay, in Daoy (p=0.03), UW-228 (p=0.05), and MDA-
MB231T (p=0.003) cells. As shown in Supplementary
Fig. 2a, although the rate of internalization of SNALP
miR-199b-5p was significantly lower compared to the other
cell lines investigated here, the cell proliferation rates were
still impaired in these cells.
SNALP miR-199b-5p treatment of several cancer cell lines
leads to impairment of Hes-1 mRNA and protein expression
To see if the biological effects on cell proliferation directly
influence the downregulation of the miR-199b-5p target, we
analyzed the levels of Hes-1 mRNA and the Hes-1 protein
in all of the cell lines investigated here. First, we performed
Fig. 1 MiR-199b-5p delivery by SNALPs, and impairment of prolif-
eration rates in different cell lines. Top for each tumorigenic cell line
analyzed (colon cancer CaCo-2 and SW480 cells, breast cancer MCF-7
cells, prostate cancer PC-3 cells, glioblastoma U-87 cells, and MB
ONS-76 cells), the histograms indicate the miR-199b-5p expression
after treatment with SNALP miRNA 199b-5p and SNALP scramble,
using TaqMan PCR assays. The Y-axis indicates miRNA 199b-5p
expression as fold changes over SNALP scramble, and the X-axis
indicates the analysis times (h). Bottom Cell index assays as a measure
for cell proliferation of the tumorigenic cell lines after the same treat-
ments. The Y-axis indicates the impedance (proportional to cell numb-
ers) and the X-axis indicates the analysis times (h). Green line
treatment with SNALP scramble, red line treatment with SNALP
miR-199b-5p. Symbols (below the red and green curves) indicate the
times of SNALP administration to cells: asterisks (below the X-axis)
are indicating the time of added medium with fetal bovine serum in the
plates, number sign 24 h after treatment, section sign 72 h after
treatment
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Western blotting to determine the basal levels of the Hes-1
protein, and as shown in Supplementary Fig. 2c, we found
different endogenous expression of the Hes-1 protein across
these different cell lines. It should be noted here that the
Hes-1 endogenous protein was revealed using polyclonal
antibodies, which showed a nonspecific protein band (the
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lower protein band in Supplementary Fig. 2c), which was
visible in almost all of the cell lines investigated here, except
for the SW480 and MCF-7 cells. This is due to the specific
antibodies used here for this assay (see “Material and meth-
ods”). Our previous study showed the regulation of Hes-1
mRNA stability by miR-199b-5p (Garzia et al. 2009). Here,
we used Syber qRT-PCR to investigate whether treatment
with 50 μg/ml SNALP miR-199b-5p affects Hes-1 mRNA
levels due to this target regulation at the mRNA level by miR-
199b-5p. As shown in Fig. 2a, Hes-1 mRNAwas downregu-
lated in all of the cell lines analyzed here (with 40 % to 80 %
mRNA target inhibition at 72 h; p values: CaCo-2, 0.02;
MCF-7, 0.03; PC-3, 0.0001; ONS-76, 0.05; Daoy, 0.01;
UW-228, 0.02; MDA-MB231T, 0.003; and HT-29, 0.01),
with the exception of the SW480, U-87, and ONS-76 cells
(for 2ΔCt values, see Supplementary Table 2). These data
prompted us to evaluate the mRNA expression of the other
miR-199b-5p targets that have been described in the literature
for these cell lines that appeared not to be affected by the miR-
199b-5p (Wang et al. 2011; Favreau et al. 2012). We, thus,
evaluated mRNA expression ofDDR1,Hif-1α, and PODXL-1
in these cell lines. At the same time as that used for miR-199b-
5p expression (72 h of treatment), we observed weak reduc-
tions inDDR1mRNA in the ONS-76, SW480, and U-87 cells
(from 15 % to 20 % mRNA target inhibition), as shown in
Fig. 2b. For the other gene targets analyzed here, only
PODXL-1 showed regulation in the ONS-76 cells (from
10 % to 15 % mRNA target inhibition), while the Hif-1α
mRNA was not significantly affected by the SNALP miR-
199b-5p delivery and overexpression at this analysis time in
these cells (for 2ΔCt values, see Supplementary Table 2).
Overall, these data strengthen the effects on Hes-1 as the main
target gene in the cells analyzed here at this particular time of
inhibition using this SNALP delivery methodology. The data
presented here also suggest that the analysis of mRNA levels
cannot be used alone as the main methodology for the dem-
onstration of downregulation of these miR-199b-5p targets.
For this reason, after the treatments, we also analyzed the
regulation of Hes-1 by Western blotting (see Fig. 2c).
Supplementary Fig. 3a shows densitometry analyses obtained
from Western blotting data normalized according to the β-
actin expression, showing the levels of Hes-1 in cells treated
with SNALP miR-199b-5p (red line) and SNALP scramble
(green line) for 72 h (see Supplementary Table 3). The nor-
malized data were obtained as ratios of the densitometric Hes-
1 protein values between the cells treated with SNALP miR-
199b-5p and with SNALP scramble. The levels of the Hes-1
protein are additionally shown in Fig. 2d. Here, there was
greater downregulation of this miR-199b-5p target only in
Daoy, UW-228, and HT-29 cells at 72 h of treatment, while
in the Caco-2, SW480, PC-3, U-87, ONS-76, MDA-MB-
231 T, and MCF-7 cells, we can consider that the turnover
of Hes-1 protein synthesis can overcome the downregulation
by miR-199b-5p at 72 h of treatment (see Fig. 2d). These data
suggest that after the treatment with SNALP miR-199b-5p, it
is only in these cells that there is a better molar ratio of
synthetic miR-199-5p and its mRNA target to allow the best
downregulation of Hes-1 that can then be translated into
regulation at the protein level. Taken altogether, here, we
can conclude that SNALP miR-199b-5p can penetrate into
these cells, which can, thus, be used as models for future in
vivo applications in animal models of these cancer types.
SNALP miR-199b-5p modifies the expression levels
of markers associated to cancer stem cells
Due to our previous findings that demonstrated that miR-
199b-5p impairs the CSC compartment (CD133+ cells) both
in vitro and in vivo in MB (Garzia et al. 2009), we also
analyzed here the effects of SNALP miR-199b-5p (after
72 h of treatment) on protein markers associated to CSCs,
i.e., on markers such as CD15 (Singh et al. 2004; Read et al.
2009; Ward et al. 2009; Andolfo et al. 2012), CD133 (Ieta et
al. 2008; Shmelkov et al. 2008; Bertrand et al. 2012), and
CD44 (Sheridan et al. 2006). We investigated CD15 and
CD133 protein expression in Daoy and UW-228 cells, and
also CD133 in HT-29 cells, which is known to be a better
characterized CSC-associated marker in colon cancer. As
shown in Fig. 3a, SNALP miR-199b-5p impaired the ex-
pression of CD133 and CD15 at 72 h in the MB cell lines
(Daoy and UW-228 cells) that showed greater impairment of
Hes1 protein levels. Similarly, the protein levels of CD133
in the HT-29 cells treated with 50 μg/ml SNALP miR-199b-
5p were downregulated (Fig. 3a), while in these HT-29 cells,
25 μg/ml SNALP miR-199b-5p showed no differences
compared to SNALP scramble (Supplementary Fig. 1b).
This provides further indirect evidence of the best efficacy
of delivery of SNALP miR199b-5p into these cells at 72 h,
as previously shown for the evaluation of Hes-1 downregu-
lation (see also Supplementary Fig. 1c).
Fig. 2 Downregulation of Hes-1 mRNA, the Hes-1 protein, and
DDR1, PODXL-1, and Hif-1α mRNAs in several cancer cell lines after
treatment with SNALP miR-199b-5p. a Downregulation of Hes-1
mRNA expression analyzed by Syber qRT-PCR after 72-h treatment
with SNALP miR-199b-5p and SNALP scramble in colon cancer
CaCo-2 and HT-29 cells, breast cancer MCF-7 and MDA-MB231T
cells, prostate cancer PC-3 cells, and MB ONS-76, Daoy and UW-228
cells. b Variations in DDR1, PODXL-1, and Hif-1α mRNA expression
analyzed by Syber qRT-PCR after 72 h of treatment with SNALP miR-
199b-5p and SNALP scramble in colon cancer SW480, MB ONS-76,
and glioblastoma U-87 cells. c Downregulation of the Hes-1 protein in
different cell lines after 72 h of treatment with SNALP miR-199b-5p
and SNALP scramble in colon cancer CaCo-2, SW480, and HT-29
cells; breast cancer MCF-7 and MDA-MB231T cells; prostate cancer
PC-3 cells; glioblastoma U-87 cells; and MB ONS-76, Daoy and UW-
228 cells. d Densitometry of Hes-1 protein expression in all of the cell
lines at 72 h. The normalized data were obtained from the ratio of the
densitometry Hes-1 protein values between the cells treated with
SNALP miR-199b-5p and with SNALP scramble
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Fig. 3 Impairment of expression of cancer stem cell-associated markers
in the different cell lines after miR-199b-5p delivery by SNALPs. a
Evaluation of expression of CSC markers in different cell lines after
72 h of treatment with SNALP miR-199b-5p and SNALP scramble in
colon cancer HT-29 cells, breast cancer MDA-MB231T cells, and MB
Daoy and UW-228 cells. bModel for the impairment of CSC-associated
markers by miR-199b-5p effects on its targets Hes-1, PODXL-1, DDR1,
and Hif-1α in the various cell lines analyzed (as indicated)
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For the evaluation of the CD44 marker, as reported by
Sheridan et al., MDA-MB231T cells are known to already
show high proportions of positive cells to these markers, as
in particular, CD44+/CD24− (98 %), as compared to MCF-7
cells that do not have these markers (see Sheridan et al.
2006). For this reason, we analyzed the effects of SNALP
miR-199b-5p on CD44 in MDA-MB231T cells, and as
shown in Fig. 3a, SNALP miR-199b-5p also impaired their
CD44 expression.
As previously demonstrated (Garzia et al. 2009), we have
confirmed here that through actions on its targets (as shown
in the model in Fig. 3b), miR-199b-5p can negatively reg-
ulate the expression of markers associated with CSCs in MB
and that miR-199b-5p also has a function in other tumori-
genic cell lines, such as those representative of colon and
breast cancers.
Discussion
MiRNAs participate in the regulation of almost every cellu-
lar process. In particular, they are useful tools for the silenc-
ing of cancers, and thus, they might act through the control
of multiple target genes. We previously defined the func-
tions of the miRNA miR-199b-5p in MB, whereby we
demonstrated direct inhibition of the target Hes-1, a down-
stream effector of both the Notch and SHH signaling path-
ways. Furthermore, miR-199b-5p impairs CD133+ cells,
which have been identified as markers of the CSC compart-
ment in MB and as active agents of tumor growth in the
orthotropic MB mouse model (Turner et al. 2010). We
recently identified negative feedback regulation of Hes-1
through its binding to the miR-199b-5p promoter region.
Additionally, we studied another target, CD15, as another
marker associated with CSCs in MB (Andolfo et al. 2012).
The Notch pathway has a crucial role in different tumor
types. Notch signaling is known to control proliferation of
stem and progenitor cells as well as cell fate specification
and differentiation in the colon, and it is necessary for
adenoma subtype formation in the APC mutant mouse
(Katoh 2008; Reedijk et al. 2008). In breast cancer, the
inhibition of Notch signaling has been shown to hinder the
survival of breast CSCs (Mittal et al. 2009; Efferson et al.
2010) as well as to reverse the tumorigenic potential of
breast cancer cell lines, which suggests that Notch signaling
has a key role in the pathogenesis of breast cancer. In MB,
the Notch/Hes-1 role remains under debate because data in
the recent literature have indicated that the Notch pathway is
not essential for SHH-driven MB genesis and that the main-
tenance of Notch signaling is not essential for initiation,
engraftment, or maintenance of SHH pathway-driven MB
(Hatton et al. 2010). This interpretation is supported by a
study by Julian et al., where they evaluated MB formation in
the absence of RBP-J, which represents a convergence point
for all of the Notch pathways (Julian et al. 2010). They
showed that the canonical Notch target gene, Hes-1, is not
downregulated by treatment with the Notch inhibitor MRK-
003 in SmoA1 tumors. They speculated that Hes-1 is both a
canonical Notch target gene and a noncanonical SHH target
gene, whereas Notch1, Notch2, and Hes5 are targets of
Notch signaling but not of SHH signaling. In the setting of
chronic SHH pathway activation in the SmoA1 cerebellum,
γ-secretase inhibitor treatments alter Notch1, Notch2, and
Hes5 expression but do not affect SHH-mediated Hes-1
expression (Fouladi et al. 2011).
Targeted delivery is one of the most studied areas in
cancer gene therapy. A large number of studies have dem-
onstrated the in vivo tumor targeting of nucleic acids using
nanocarriers (Judge et al. 2009). Once injected into the
blood stream, stealth nanocarriers accumulate in tumors
due to their enhanced permeability and retention effects.
Moreover, in the case of nucleic acids, there is also the need
for the use of transfection strategies that provide for their
protection against degradation and promote their efficient
uptake into the target cells.
Cationic liposomes are certainly the most investigated
nanotechnology-based delivery system for nucleic acid de-
livery. However, the efficiency of these carriers can be
limited by their physical instability in vivo, followed by
their complexing with nucleic acids (Oh and Park 2009).
SNALPs can be considered as an evolution of these cationic
liposomes that can encapsulate nucleic acids into their in-
ternal aqueous cavity and thus stabilize them in biological
fluids (Semple et al. 2010). Furthermore, the potential of
this system for tumor targeting has been demonstrated
(Leonetti et al. 2001).
In the present study, we developed a single-stranded 2′-
OMe-miR-199b-5p that was loaded into SNALPs, and we
have demonstrated that this synthetic miRNA has thermal
stability and nuclease resistance in cells for treatments of up
to 72 h, as shown by TaqMan RT-PCR.
With our treatment, we also observed different efficacies
of SNALP miR-199b-5p delivery in different cell lines,
which is probably linked to the variable compositions of
the cell membranes and the differing abilities of these cells
to internalize SNALPs; this might further be due to the
different proliferation rates of these cells, which would lead
to different dilution effects. To define the significant levels
of these effects in the HT-29 cells, we tested two different
SNALP miR-199b-5p concentrations. We further demon-
strated that after 72 h of treatment, SNALP miR-199b-5p
induces Hes-1 protein downregulation and impairs cell pro-
liferation in several cell types. Here, we observed different
effects on Hes-1 downregulation that might be due to vari-
able basal levels of the Hes-1 protein in these various cell
types (as shown in Supplementary Fig. 2c) and different
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levels of internalization of the miR-199b-5p in these cells
after SNALP miR-199b-5p treatment, thus further affecting
cell proliferation. Indeed, we speculate that we have greater
downregulation of Hes-1 only in Daoy, UW-228, and HT-29
cells because here we obtained better ratios of target expres-
sion and miR-199b-5p levels, such as will promote the
regulation of Hes-1.
In terms of the inhibition of cell proliferation, this deliv-
ery with SNALP miR-199b-5p appears to be cell-type de-
pendent, and this effect might be due to the other genes that
are involved in the regulation of cell proliferation and direct
targets of miR-199b-5p (PODXL, DDR1, and HIF-1α). In a
study by Wang et al., for example, they suggested that miR-
199b-5p negatively regulates cell growth by downregulation
of hypoxia-induced HIF-1α in hepatocellular carcinoma
(Wang et al. 2011). We also found that the CSCs-
associated markers CD133 and CD15 (MB), CD133 (colo-
rectal cancer cells) and CD44 (breast cancer cells) are also
downregulated, suggesting that SNALP miR-199b-5p can
also regulate CSC protein signaling and physiology through
downregulation of the miR-199b-5p target, making this
system a useful tool for in vivo application. These concepts
now require further efforts for the evaluation of the effects
of SNALP miR-199b-5p on CSCs properties in vivo in
these hypoxic microenvironmental tumor tissues (Magee et
al. 2012) where these cells reside.
The impairment of CD44 expression can be ascribed to
the substantial direct inhibition of Hes-1 and its involvement
in SHH-driven signaling. CD44 is not a direct target of miR-
199b-5p. Indeed, Wu et al. showed a direct correlation
between Hes-1 and CD44 expressions during differentiation
processes in neuroepithelial cells (Wu et al. 2003). Here, we
analyzed the correlation between Hes-1 and CD44 expres-
sions in breast cancer MDA-MB231T cells as an indirect
effect of Hes-1 downregulation by miR-199-5p. Moreover,
as shown by Shen et al. in human hepatocellular carcinoma,
deregulation of miR-199-5p is involved in malignant pro-
gression, which will further impair the ability of the cells to
cross an extracellular matrix (Shen et al. 2010). The authors
here speculated that miR-199b-5p can modulate cell inva-
sion by targeting DDR1, a discoidin domain receptor. In
addition, Kim and Nam (2006) showed that DDR1 can
promote the nuclear translocation of Notch1, with regulation
of its downstream pathway targets, like Hes-1. Here, we
found DDR1 mRNA downregulation in the same cell lines
(SW480, U-87, and ONS76 cells) treated with SNALP miR-
199b-5p. Thus, we speculate that the impaired proliferation
function observed in these cell lines at this time is driven by
SNALP miR-199b-5p by direct downregulation of DDR-1.
Furthermore, at this time, we cannot exclude that other
target genes of miR-199b-5p can influence cell proliferation,
as the early events of cell proliferation (e.g., at 24 h of
analysis) are most probably the early targets during the
SNALP miR-199b-5p delivery into the cells. Future studies
will need to address whether the downregulation of DDR1
has a cooperative effect on the modulation of the Notch
pathway and if the impairment of CSC-associated markers
is due to the effects of miR-199b-5p on both of its targets
(i.e., Hes-1 and DDR1), as shown in our model in Fig. 3b.
Finally, here, we can conclude that SNALP miR-199b-5p
and its use in the treatment of these cell lines did not show
any cytotoxicity effects (see Supplemental Materials and
Supplementary Fig. 3b–d), which represents a fundamental
property for its eligibility as a therapeutic approach and for
limiting the use of the more aggressive current therapies,
such as chemotherapy agents, which can cause several and
severe side effects.
Conclusions
We have provided here the basis for therapies based on the
miRNA miR-199b-5p through the development of SNALPs
that contain miR-199b-5p. This SNALP miR-199b-5p has
high delivery efficiency and low cytotoxicity, while increas-
ing the miR-199b-5p cellular uptake. Further studies in
preclinical models are now being performed to assess the
impact of off-target in vivo delivery of SNALP miR-199b-
5p in different cancer types to define its efficacy and to
transfer the use of SNALP miR-199b-5p to clinical trials
in human.
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